Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-26 @ 2:00 AM
Study NCT ID:
NCT00118105
Status:
WITHDRAWN
Last Update Posted:
2013-01-03
First Post:
2005-07-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D009362', 'term': 'Neoplasm Metastasis'}, {'id': 'D003110', 'term': 'Colonic Neoplasms'}, {'id': 'D012004', 'term': 'Rectal Neoplasms'}], 'ancestors': [{'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}, {'id': 'D009385', 'term': 'Neoplastic Processes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'D000069287', 'term': 'Capecitabine'}, {'id': 'D000077150', 'term': 'Oxaliplatin'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}, {'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}}, 'statusModule': {'whyStopped': 'Budget Constraints', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2006-11'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-01', 'completionDateStruct': {'date': '2007-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-01-02', 'studyFirstSubmitDate': '2005-07-08', 'studyFirstSubmitQcDate': '2005-07-08', 'lastUpdatePostDateStruct': {'date': '2013-01-03', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2005-07-11', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2007-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients with R0 resection after treatment', 'timeFrame': '16-18 weeks from registration'}, {'measure': 'Probability of nonprogression (i.e., stable disease or response [complete and partial, confirmed and unconfirmed])', 'timeFrame': '12 weeks from registration'}, {'measure': 'Comparison of patients achieving R0 resection with literature', 'timeFrame': '16-18 weeks from registration'}, {'measure': 'Overall survival', 'timeFrame': 'Up to 3 years'}, {'measure': 'Disease-free survival', 'timeFrame': 'Up to 3 years'}, {'measure': 'Positron emission tomography response', 'timeFrame': 'Registration and 12 weeks'}, {'measure': 'Correlation of clinical outcome with expression of biomarkers and telomere length', 'timeFrame': 'Up to 3 years'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['recurrent colon cancer', 'stage IV colon cancer', 'recurrent rectal cancer', 'stage IV rectal cancer', 'liver metastases'], 'conditions': ['Colorectal Cancer', 'Metastatic Cancer']}, 'referencesModule': {'references': [{'pmid': '16635283', 'type': 'BACKGROUND', 'citation': 'Abdalla EK, Eng C, Madary A, Vauthey JN; Southwest Oncology Group 0408. Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver. Clin Colorectal Cancer. 2006 Mar;5(6):436-9. doi: 10.3816/ccc.2006.n.015. No abstract available.'}]}, 'descriptionModule': {'briefSummary': 'RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving capecitabine and oxaliplatin together with bevacizumab before and after surgery may be an effective treatment for liver metastases.\n\nPURPOSE: This phase II trial is studying how well giving capecitabine and oxaliplatin together with bevacizumab works in treating patients who are undergoing surgery for liver metastases due to colorectal cancer.', 'detailedDescription': 'OBJECTIVES:\n\n* Determine the proportion of patients with resectable hepatic metastases secondary to colorectal cancer who undergo surgical resection and achieve a R0 resection after treatment with neoadjuvant capecitabine, oxaliplatin, and bevacizumab.\n* Determine the probability of non-progression (i.e., stable disease or response \\[complete and partial, confirmed and unconfirmed\\]) in patients treated with this regimen.\n* Compare the proportion of patients treated with this regimen who undergo surgical resection and those who achieve a R0 resection with that described in the literature.\n* Determine overall survival and disease-free survival of patients treated with this regimen.\n* Determine response by positron emission tomography in patients treated with this regimen.\n* Correlate clinical outcome with expression of biomarkers (e.g., thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, excision repair cross complementing 1, and hTERT) and telomere length in patients treated with this regimen.\n\nOUTLINE: This is a multicenter study.\n\n* Neoadjuvant therapy: Patients receive bevacizumab\\* IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nNOTE: \\*Bevacizumab is administered during courses 1-3 of neoadjuvant therapy.\n\n* Surgery: Approximately 3-4 weeks after completion of neoadjuvant therapy, patients are evaluated. Patients with unresectable disease are removed from the study. Patients with resectable disease undergo surgical resection of liver metastases within 4-6 weeks after completion of neoadjuvant therapy.\n* Adjuvant therapy: Beginning at least 28 days after surgical resection, patients with at least stable disease after completion of neoadjuvant therapy receive 4 courses of adjuvant bevacizumab\\*\\*, oxaliplatin, and capecitabine as in neoadjuvant therapy.\n\nNOTE: \\*\\*Bevacizumab is administered during courses 1-4 of adjuvant therapy.\n\nAfter completion of study treatment, patients are followed every 4 months until disease progression and then every 6 months for up to 3 years from study entry.\n\nPROJECTED ACCRUAL: Approximately 35-65 patients will be accrued for this study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'DISEASE CHARACTERISTICS:\n\n* Diagnosis of hepatic metastases secondary to colorectal cancer by percutaneous hepatic biopsy\n* Resectable hepatic metastases by any of the following:\n\n * Minor resection (i.e., less than a hemihepatectomy)\n * Major resection (i.e., hemihepatectomy or extended hepatectomy)\n * Bilobar resection (including atypical resection)\n* Synchronous primary tumor and hepatic metastases allowed\n* Radiologic evidence of hepatic metastases by multiphasic contrast-enhanced spiral CT scan\n* Resectable primary colorectal cancer that is in place allowed\n* Measurable disease\n* No evidence of extrahepatic metastases by chest x-ray or CT scan of the chest\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nPerformance status\n\n* Zubrod 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Hemoglobin ≥ 9.0 g/dL\n* WBC ≥ 3,000/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Absolute neutrophil count ≥ 1,500/mm\\^3\n\nHepatic\n\n* Bilirubin ≤ 2 times upper limit of normal (ULN)\n* SGOT or SGPT ≤ 2.5 times ULN\n\nRenal\n\n* Creatinine clearance ≥ 60 mL/min\n* Urine protein/creatinine ratio \\< 1 OR\n* Urine protein \\< 1 g by 24-hour urine collection\n\nCardiovascular\n\n* No uncontrolled hypertension (i.e., blood pressure \\> 150/90 mm Hg)\n\n * History of hypertension allowed provided it is well controlled on a stable regimen of anti-hypertensive therapy\n* No arterial thromboembolic event within the past 12 months, including any of the following:\n\n * Transient ischemic attack\n * Cerebrovascular accident\n * Unstable angina\n * Myocardial infarction\n* No peripheral vascular disease ≥ grade 2\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No pre-existing peripheral neuropathy ≥ grade 2\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* More than 6 months since prior adjuvant chemotherapy for the primary tumor\n* No prior systemic chemotherapy for metastatic disease\n* No prior hepatic artery infusion chemotherapy for metastatic disease\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* No prior radiotherapy for metastatic disease\n\nSurgery\n\n* More than 7 days since prior colonoscopy or fine needle aspiration\n* More than 28 days since prior major invasive surgery or open biopsy\n\nOther\n\n* At least 4 weeks since prior and no concurrent sorivudine or brivudine\n* No prior radiofrequency ablation for metastatic disease\n* No prior cryotherapy for metastatic disease\n* No other prior ablative techniques for metastatic disease\n* No concurrent cimetidine\n\n * Concurrent ranitidine or other drug from a different antiulcer class allowed\n* No concurrent oral anticoagulation for treatment of thrombosis\n\n * Concurrent warfarin (1 mg) to maintain patency of central venous catheter allowed'}, 'identificationModule': {'nctId': 'NCT00118105', 'briefTitle': 'S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer', 'organization': {'class': 'NETWORK', 'fullName': 'SWOG Cancer Research Network'}, 'officialTitle': 'A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin, and Bevacizumab for Resectable Colorectal Metastases in the Liver', 'orgStudyIdInfo': {'id': 'CDR0000433491'}, 'secondaryIdInfos': [{'id': 'S0408', 'type': 'OTHER', 'domain': 'SWOG'}, {'id': 'U10CA032102', 'link': 'https://reporter.nih.gov/quickSearch/U10CA032102', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Chemotherapy + Surgery + Chemotherapy', 'description': 'Preoperative Neoadjuvant Chemotherapy\n\n* Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3\n* Oxaliplatin, 130 mg/m\\^2, IV, Day 1 of cycles 1,2,3,4\n* Capecitabine, 1,700 mg/m\\^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4\n\nConventional surgery: After 4 cycles of chemotherapy\n\nPostoperative Neoadjuvant Chemotherapy\n\n* Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4\n* Oxaliplatin, 130 mg/m\\^2, IV, Day 1 of cycles 1,2,3,4\n* Capecitabine, 1,700 mg/m\\^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4', 'interventionNames': ['Biological: bevacizumab', 'Drug: capecitabine', 'Drug: oxaliplatin', 'Procedure: conventional surgery']}], 'interventions': [{'name': 'bevacizumab', 'type': 'BIOLOGICAL', 'otherNames': ['Avastin', 'NSC-704865'], 'description': 'Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4', 'armGroupLabels': ['Chemotherapy + Surgery + Chemotherapy']}, {'name': 'capecitabine', 'type': 'DRUG', 'otherNames': ['Xeloda', 'NSC-712807'], 'description': 'Pre \\& Post Operative: 1,700 mg/m\\^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4', 'armGroupLabels': ['Chemotherapy + Surgery + Chemotherapy']}, {'name': 'oxaliplatin', 'type': 'DRUG', 'otherNames': ['NSC-266046'], 'description': '130 mg/m\\^2, IV, Day 1 of cycles 1,2,3,4', 'armGroupLabels': ['Chemotherapy + Surgery + Chemotherapy']}, {'name': 'conventional surgery', 'type': 'PROCEDURE', 'description': 'Resection', 'armGroupLabels': ['Chemotherapy + Surgery + Chemotherapy']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90089-9181', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'USC/Norris Comprehensive Cancer Center and Hospital', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '60507', 'city': 'Aurora', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush-Copley Cancer Care Center', 'geoPoint': {'lat': 41.76058, 'lon': -88.32007}}, {'zip': '60435', 'city': 'Joliet', 'state': 'Illinois', 'country': 'United States', 'facility': 'Joliet Oncology-Hematology Associates, Limited - West', 'geoPoint': {'lat': 41.52519, 'lon': -88.0834}}, {'zip': '61801', 'city': 'Urbana', 'state': 'Illinois', 'country': 'United States', 'facility': 'Carle Cancer Center at Carle Foundation Hospital', 'geoPoint': {'lat': 40.11059, 'lon': -88.20727}}, {'zip': '61801', 'city': 'Urbana', 'state': 'Illinois', 'country': 'United States', 'facility': 'CCOP - Carle Cancer Center', 'geoPoint': {'lat': 40.11059, 'lon': -88.20727}}, {'zip': '46107', 'city': 'Beech Grove', 'state': 'Indiana', 'country': 'United States', 'facility': 'St. Francis Hospital and Health Centers - Beech Grove Campus', 'geoPoint': {'lat': 39.72199, 'lon': -86.08998}}, {'zip': '46360', 'city': 'Michigan City', 'state': 'Indiana', 'country': 'United States', 'facility': 'Saint Anthony Memorial Health Centers', 'geoPoint': {'lat': 41.70754, 'lon': -86.89503}}, {'zip': '47374', 'city': 'Richmond', 'state': 'Indiana', 'country': 'United States', 'facility': 'Reid Hospital & Health Care Services, Incorporated', 'geoPoint': {'lat': 39.82894, 'lon': -84.89024}}, {'zip': '67401', 'city': 'Salina', 'state': 'Kansas', 'country': 'United States', 'facility': 'Tammy Walker Cancer Center at Salina Regional Health Center', 'geoPoint': {'lat': 38.84028, 'lon': -97.61142}}, {'zip': '02118', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Cancer Research Center at Boston Medical Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '49007-3731', 'city': 'Kalamazoo', 'state': 'Michigan', 'country': 'United States', 'facility': 'West Michigan Cancer Center', 'geoPoint': {'lat': 42.29171, 'lon': -85.58723}}, {'zip': '49007', 'city': 'Kalamazoo', 'state': 'Michigan', 'country': 'United States', 'facility': 'Bronson Methodist Hospital', 'geoPoint': {'lat': 42.29171, 'lon': -85.58723}}, {'zip': '49001', 'city': 'Kalamazooaa', 'state': 'Michigan', 'country': 'United States', 'facility': 'Borgess Medical Center'}, {'zip': '59101', 'city': 'Billings', 'state': 'Montana', 'country': 'United States', 'facility': 'CCOP - Montana Cancer Consortium', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '59101', 'city': 'Billings', 'state': 'Montana', 'country': 'United States', 'facility': 'Hematology-Oncology Centers of the Northern Rockies - Billings', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '59101', 'city': 'Billings', 'state': 'Montana', 'country': 'United States', 'facility': 'Northern Rockies Radiation Oncology Center', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '59101', 'city': 'Billings', 'state': 'Montana', 'country': 'United States', 'facility': 'St. Vincent Healthcare', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '59107-5100', 'city': 'Billings', 'state': 'Montana', 'country': 'United States', 'facility': 'Billings Clinic Cancer Center', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '59107-7000', 'city': 'Billings', 'state': 'Montana', 'country': 'United States', 'facility': 'Deaconess Billings Clinic - Downtown', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '59715', 'city': 'Bozeman', 'state': 'Montana', 'country': 'United States', 'facility': 'Bozeman Deaconess Cancer Center', 'geoPoint': {'lat': 45.67965, 'lon': -111.03856}}, {'zip': '59701', 'city': 'Butte', 'state': 'Montana', 'country': 'United States', 'facility': 'St. James Community Hospital', 'geoPoint': {'lat': 46.00382, 'lon': -112.53474}}, {'zip': '59405', 'city': 'Great Falls', 'state': 'Montana', 'country': 'United States', 'facility': 'Frontier Cancer Center', 'geoPoint': {'lat': 47.50024, 'lon': -111.30081}}, {'zip': '59405', 'city': 'Great Falls', 'state': 'Montana', 'country': 'United States', 'facility': 'Great Falls Clinic', 'geoPoint': {'lat': 47.50024, 'lon': -111.30081}}, {'zip': '59601', 'city': 'Helena', 'state': 'Montana', 'country': 'United States', 'facility': "St. Peter's Hospital", 'geoPoint': {'lat': 46.59271, 'lon': -112.03611}}, {'zip': '59901', 'city': 'Kalispell', 'state': 'Montana', 'country': 'United States', 'facility': 'Glacier Oncology, PLLC', 'geoPoint': {'lat': 48.19579, 'lon': -114.31291}}, {'zip': '59901', 'city': 'Kalispell', 'state': 'Montana', 'country': 'United States', 'facility': 'Kalispell Medical Oncology', 'geoPoint': {'lat': 48.19579, 'lon': -114.31291}}, {'zip': '59901', 'city': 'Kalispell', 'state': 'Montana', 'country': 'United States', 'facility': 'Kalispell Regional Medical Center', 'geoPoint': {'lat': 48.19579, 'lon': -114.31291}}, {'zip': '59801', 'city': 'Missoula', 'state': 'Montana', 'country': 'United States', 'facility': 'Community Medical Center', 'geoPoint': {'lat': 46.87215, 'lon': -113.994}}, {'zip': '59804', 'city': 'Missoula', 'state': 'Montana', 'country': 'United States', 'facility': 'Guardian Oncology and Center for Wellness', 'geoPoint': {'lat': 46.87215, 'lon': -113.994}}, {'zip': '59807-7877', 'city': 'Missoula', 'state': 'Montana', 'country': 'United States', 'facility': 'Montana Cancer Specialists at Montana Cancer Center', 'geoPoint': {'lat': 46.87215, 'lon': -113.994}}, {'zip': '59807', 'city': 'Missoula', 'state': 'Montana', 'country': 'United States', 'facility': 'Montana Cancer Center at St. Patrick Hospital and Health Sciences Center', 'geoPoint': {'lat': 46.87215, 'lon': -113.994}}, {'zip': '27534', 'city': 'Goldsboro', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wayne Memorial Hospital, Incorporated', 'geoPoint': {'lat': 35.38488, 'lon': -77.99277}}, {'zip': '45405', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Grandview Hospital', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '45406', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Good Samaritan Hospital', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '45409', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'David L. Rike Cancer Center at Miami Valley Hospital', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '45415', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Samaritan North Cancer Care Center', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '45428', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Dayton', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '45429', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'CCOP - Dayton', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '45840', 'city': 'Findlay', 'state': 'Ohio', 'country': 'United States', 'facility': 'Blanchard Valley Medical Associates', 'geoPoint': {'lat': 41.04422, 'lon': -83.64993}}, {'zip': '45429', 'city': 'Kettering', 'state': 'Ohio', 'country': 'United States', 'facility': 'Charles F. Kettering Memorial Hospital', 'geoPoint': {'lat': 39.6895, 'lon': -84.16883}}, {'zip': '45801', 'city': 'Lima', 'state': 'Ohio', 'country': 'United States', 'facility': "St. Rita's Medical Center", 'geoPoint': {'lat': 40.74255, 'lon': -84.10523}}, {'zip': '45044', 'city': 'Middletown', 'state': 'Ohio', 'country': 'United States', 'facility': 'Middletown Regional Hospital', 'geoPoint': {'lat': 39.51506, 'lon': -84.39828}}, {'zip': '45373-1300', 'city': 'Troy', 'state': 'Ohio', 'country': 'United States', 'facility': 'UVMC Cancer Care Center at Upper Valley Medical Center', 'geoPoint': {'lat': 40.0395, 'lon': -84.20328}}, {'zip': '45385', 'city': 'Xenia', 'state': 'Ohio', 'country': 'United States', 'facility': 'Ruth G. McMillan Cancer Center at Greene Memorial Hospital', 'geoPoint': {'lat': 39.68478, 'lon': -83.92965}}, {'zip': '24541', 'city': 'Danville', 'state': 'Virginia', 'country': 'United States', 'facility': 'Danville Regional Medical Center', 'geoPoint': {'lat': 36.58597, 'lon': -79.39502}}, {'zip': '82801', 'city': 'Sheridan', 'state': 'Wyoming', 'country': 'United States', 'facility': 'Welch Cancer Center at Sheridan Memorial Hospital', 'geoPoint': {'lat': 44.79719, 'lon': -106.95618}}], 'overallOfficials': [{'name': 'Jean-Nicolas Vauthey, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'M.D. Anderson Cancer Center'}, {'name': 'Robert de W. Marsh, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Florida'}, {'name': 'Cathy Eng, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'M.D. Anderson Cancer Center'}, {'name': 'Henry Q. Xiong, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'M.D. Anderson Cancer Center'}, {'name': 'Kevin G. Billingsley, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'OHSU Knight Cancer Institute'}, {'name': 'Steven A. Curley, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'M.D. Anderson Cancer Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'SWOG Cancer Research Network', 'class': 'NETWORK'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}, {'name': 'Eastern Cooperative Oncology Group', 'class': 'NETWORK'}], 'responsibleParty': {'type': 'SPONSOR'}}}}